Phase II clinical studies demonstrated enhanced tumor uptake and anti-tumor activity for this antibody in the presence of interferon (IFN) which promoted increased tumor antigen expression and localization compared to the use of the 131I-CC49 antibody alone (153). Here, IFNA1 is linked to neoplasm.